Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals

作者
Alex Durand Nka,Yagaï Bouba,Georges Této,Ezéchiel Ngoufack Jagni Semengue,Désiré Takou,Aurelie Minelle Kengni Ngueko,Lavinia Fabeni,Luca Carioti,Daniele Armenia,Willy Pabo,Béatrice Dambaya,Samuel Martin Sosso,Vittorio Colizzi,Carlo Federico Perno,Francesca Ceccherini‐Silberstein,Maria Mercedes Santoro,Joseph Fokam,Alexis Ndjolo
出处
期刊:Journal of Antimicrobial Chemotherapy [Oxford University Press]
卷期号:78 (1): 272-275 被引量:31
标识
DOI:10.1093/jac/dkac388
摘要

OBJECTIVES: We evaluated the HIV-1 capsid genetic variability and lenacapavir drug resistance-associated mutations (DRMs) among drug-naive individuals across HIV-1 clades. METHODS: A total of 2031 HIV-1 sequences from drug-naive patients were analysed for capsid amino acid modification and the prevalence of lenacapavir DRMs. Amino acid positions with <5% variability were considered as conserved and variability was analysed by HIV-1 clades. RESULTS: Overall, 63% (148/232) of amino acid positions were conserved in the capsid protein. Of note, conservation was consistent in specific binding residues of cellular factors involved in viral replication [CypA (G89, P90), CPSF6 (Q4, N57, N74, A77, K182) and TRIM-NUP153 (R143)], while N183 (12.31%) was the only non-conserved lenacapavir binding residue. The overall prevalence (95% CI) of lenacapavir DRMs was 0.14% (0.05-0.44) (3/2031), with M66I (0.05%) and Q67H (0.05%) observed in subtype C, and T107N (0.05%) observed in CRF01_AE. Moreover, polymorphic mutations M66C (n = 85; 4.18%), Q67K (n = 78; 3.84%), K70R (n = 7; 0.34%), N74R (n = 57; 2.81%) and T107L (n = 82; 4.03%) were observed at lenacapavir resistance-associated positions. CONCLUSIONS: The low level of lenacapavir DRMs (<1%) supports its predicted effectiveness for treatment and prevention, regardless of HIV-1 clades. The established conserved regions hence serve as a hallmark for the surveillance of novel mutations potentially relevant for lenacapavir resistance.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梨涡完成签到,获得积分20
刚刚
1秒前
1秒前
SciGPT的应助被我爱学习采纳,获得10
1秒前
北走发布了新的文献求助10
2秒前
勋章发布了新的文献求助10
3秒前
未碎冰蓝完成签到,获得积分10
3秒前
无花果的应助被ahui采纳,获得30
4秒前
早睡完成签到,获得积分10
4秒前
4秒前
4秒前
一个快乐的吃货完成签到,获得积分10
5秒前
柳絮吹雪的应助被DYF采纳,获得20
5秒前
Nole的应助被半夏采纳,获得10
5秒前
5秒前
arsenal发布了新的文献求助10
5秒前
5秒前
银鞍照白马完成签到,获得积分10
6秒前
xr完成签到,获得积分10
6秒前
未碎冰蓝发布了新的文献求助30
7秒前
7秒前
SciGPT的应助被守护采纳,获得10
8秒前
初(*^▽^*)心的应助被滴滴滴滴采纳,获得10
9秒前
派大星完成签到,获得积分10
9秒前
9秒前
了了发布了新的文献求助10
9秒前
yuguo6293发布了新的文献求助20
9秒前
Nole的应助被邹益春采纳,获得30
9秒前
jiangbai完成签到,获得积分10
10秒前
大模型的应助被袁志阳采纳,获得10
10秒前
10秒前
10秒前
yuqq完成签到,获得积分10
11秒前
chasingthestars完成签到,获得积分10
11秒前
wang完成签到,获得积分10
11秒前
11秒前
11秒前
领导范儿的应助被酷酷柚子采纳,获得10
12秒前
wanci的应助被害怕的慕晴采纳,获得10
12秒前
呼啦啦完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178139
求助须知:如何正确求助?哪些是违规求助? 9568884
关于积分的说明 21801751
捐赠科研通 7773042
什么是DOI,文献DOI怎么找? 3432685
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478223